62.01
price down icon8.62%   -5.85
pre-market  Pre-mercato:  61.23   -0.78   -1.26%
loading

Incyte Corp Borsa (INCY) Ultime notizie

pulisher
06:38 AM

Analyst recommendations: Block, Incyte, Ralph Lauren, Five Below, Tesla... - Marketscreener.com

06:38 AM
pulisher
05:32 AM

Incyte Corporation (INCY): Among the Best Biotech Stocks to Buy According to Billionaires - Yahoo Finance

05:32 AM
pulisher
Mar 17, 2025

Incyte stock dives after drug trial disappoints investors - Yahoo Finance

Mar 17, 2025
pulisher
Mar 17, 2025

Incyte Corp. stock underperforms Monday when compared to competitors - MarketWatch

Mar 17, 2025
pulisher
Mar 17, 2025

RBC maintains Incyte stock with $68 target post-data release By Investing.com - Investing.com Australia

Mar 17, 2025
pulisher
Mar 17, 2025

Incyte stock tumbles despite meeting main goal in skin disease treatment trial - MSN

Mar 17, 2025
pulisher
Mar 17, 2025

Incyte (INCY) Stock Drops on Phase Three Trial Data - GuruFocus.com

Mar 17, 2025
pulisher
Mar 17, 2025

Why Incyte (INCY) Stock Is Nosediving - MSN

Mar 17, 2025
pulisher
Mar 17, 2025

Leerink says Incyte’s povo trial results disappoint, drug likely to be approved - TipRanks

Mar 17, 2025
pulisher
Mar 17, 2025

Oil pressures, Robinhood, Incyte: Market Minute - Yahoo Finance

Mar 17, 2025
pulisher
Mar 17, 2025

Top Midday Decliners -March 17, 2025 at 02:00 pm EDT - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

Incyte Reports Positive Results From Skin Therapy Study; Wells Fargo Cuts Price Target; Shares Drop - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

Mizuho Reiterates Neutral Rating on Incyte (INCY) - StreetInsider.com

Mar 17, 2025
pulisher
Mar 17, 2025

US MARKET Live, 17 March 2025: Incyte Corp, Tesla, and Dollar General among top losers on S&P 500 - Moneycontrol

Mar 17, 2025
pulisher
Mar 17, 2025

Incyte stock hit 11% despite paediatric dermatology trials hitting target - Clinical Trials Arena

Mar 17, 2025
pulisher
Mar 17, 2025

Incyte Leads S&P 500 Decliners Amidst Phase III Results of PovorcitinibNews and Statistics - IndexBox, Inc.

Mar 17, 2025
pulisher
Mar 17, 2025

Incyte Leads S&P 500 Decliners on Skin Condition Drug Trial Results - Investopedia

Mar 17, 2025
pulisher
Mar 17, 2025

Top Stock Movers Now: Intel, Netflix, Incyte, and More - Investopedia

Mar 17, 2025
pulisher
Mar 17, 2025

Incyte Is Today’s Worst S&P 500 Stock. Here’s Why. - MSN

Mar 17, 2025
pulisher
Mar 17, 2025

Nvidia, Netflix, Berkshire Hathaway, Baidu, Incyte, NCL, Affirm: Stocks to watch today - Yahoo Finance

Mar 17, 2025
pulisher
Mar 17, 2025

Incyte stock decline after results an ‘overreaction,” says Wolfe Research - TipRanks

Mar 17, 2025
pulisher
Mar 17, 2025

Incyte Stock Eyes Worst Day Since 2018 After Trial Results - Schaeffers Research

Mar 17, 2025
pulisher
Mar 17, 2025

Wells Fargo Cuts Price Target on Incyte to $58 From $70 -March 17, 2025 at 10:34 am EDT - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

Incyte could see some weakness as povo looks mostly as expected, RBC says - TipRanks

Mar 17, 2025
pulisher
Mar 17, 2025

Incyte's New Treatment for Chronic Skin Disease Shows Promising Results In Latest Clinical Trials, Stock Falls - Benzinga

Mar 17, 2025
pulisher
Mar 17, 2025

Nvidia, Netflix, Berkshire Hathaway, Baidu, Lockheed Martin, Incyte, NCL, Affirm: Stocks to watch today - MSN

Mar 17, 2025
pulisher
Mar 17, 2025

RBC maintains Incyte stock with $68 target post-data release - Investing.com

Mar 17, 2025
pulisher
Mar 17, 2025

Incyte, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga

Mar 17, 2025
pulisher
Mar 17, 2025

Buy Rating for Incyte’s Povorcitinib Despite Mixed Trial Results, Highlighting Potential in Biologic-Experienced Subgroups - TipRanks

Mar 17, 2025
pulisher
Mar 17, 2025

Stocks making the biggest moves premarket: Affirm, Netflix, Incyte, Norwegian Cruise Line and more - CNBC

Mar 17, 2025
pulisher
Mar 17, 2025

Incyte Reports Positive Data From Phase 3 STOP-HS Studies Of Povorcitinib - Nasdaq

Mar 17, 2025
pulisher
Mar 17, 2025

Incyte stock tumbles following clinical trial results By Investing.com - Investing.com Australia

Mar 17, 2025
pulisher
Mar 17, 2025

Incyte stock tumbles following clinical trial results - Investing.com

Mar 17, 2025
pulisher
Mar 17, 2025

RBC Capital on Incyte (INCY): 'Povo Looks Mostly as We Expected', 'We expect modest weakness today' - StreetInsider.com

Mar 17, 2025
pulisher
Mar 17, 2025

Incyte’s skin disease drug meets main goal in late-stage studies - The Financial Express

Mar 17, 2025
pulisher
Mar 17, 2025

Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa - BioSpace

Mar 17, 2025
pulisher
Mar 17, 2025

Incyte reports pivotal trial success for HS treatment povorcitinib - Investing.com

Mar 17, 2025
pulisher
Mar 17, 2025

S&P 500 Futures Fall in Premarket Trading; Incyte, Affirm Holdings Lag - Barron's

Mar 17, 2025
pulisher
Mar 17, 2025

Incyte's skin disease drug meets main goal in two late-stage studies -March 17, 2025 at 07:23 am EDT - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

Incyte's skin disease drug meets main goal in two late-stage studies - TradingView

Mar 17, 2025
pulisher
Mar 17, 2025

Incyte's skin disease drug meets main goal in two late-stage studies -March 17, 2025 at 07:06 am EDT - Marketscreener.com

Mar 17, 2025
pulisher
Mar 15, 2025

15 Best Biotech Stocks to Buy According to Billionaires - Insider Monkey

Mar 15, 2025
pulisher
Mar 14, 2025

INCY Opzelura Shows Superior Efficacy in 2 Prurigo Nodularis Studies - MSN

Mar 14, 2025
pulisher
Mar 14, 2025

Atopic Dermatitis Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Patient Pool, MOA, ROA and Companies by DelveInsight - Barchart

Mar 14, 2025
pulisher
Mar 13, 2025

Incyte’s SWOT analysis: stock faces patent cliff as dermatology pipeline grows By Investing.com - Investing.com South Africa

Mar 13, 2025
pulisher
Mar 12, 2025

Incyte’s SWOT analysis: stock faces patent cliff as dermatology pipeline grows - Investing.com

Mar 12, 2025
pulisher
Mar 12, 2025

Incyte (INCY) Up 2.6% Since Last Earnings Report: Can It Continue? - Yahoo Finance

Mar 12, 2025
pulisher
Mar 11, 2025

Incyte at Leerink Global Healthcare: Strategic Growth and Pipeline Focus - Investing.com

Mar 11, 2025
pulisher
Mar 11, 2025

Incyte Stock: A Deep Dive Into Analyst Perspectives (6 Ratings) - Benzinga

Mar 11, 2025
pulisher
Mar 11, 2025

Incyte stock holds as JMP maintains Market Perform rating By Investing.com - Investing.com South Africa

Mar 11, 2025
pulisher
Mar 11, 2025

Incyte stock holds as JMP maintains Market Perform rating - Investing.com

Mar 11, 2025
pulisher
Mar 10, 2025

Incyte Releases Mixed Data From Late-Stage Opzelura Studies In Skin Disease Characterized By Itchy Firm Lumps - AOL

Mar 10, 2025
pulisher
Mar 10, 2025

Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases - AOL

Mar 10, 2025
pulisher
Mar 10, 2025

TD Cowen sets Incyte stock $88 target, retains Buy rating - Investing.com

Mar 10, 2025
pulisher
Mar 10, 2025

LLY/INCY Olumiant Shows Superior Efficacy In Pediatric Alopecia Study - Barchart

Mar 10, 2025
pulisher
Mar 10, 2025

Eli Lilly, Incyte Report Significant Hair Regrowth in Adolescents Treated With Baricitinib - Marketscreener.com

Mar 10, 2025
pulisher
Mar 10, 2025

Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura®) in Patients with Prurigo Nodularis (PN) at 2025 American Academy of Dermatology Annual Meeting - BioSpace

Mar 10, 2025
pulisher
Mar 09, 2025

Incyte Corporation to Host Earnings Call - ACCESS Newswire

Mar 09, 2025
pulisher
Mar 09, 2025

Incyte, Eli Lilly present results from Phase 3 BRAVE-AA-PEDS study - TipRanks

Mar 09, 2025
pulisher
Mar 09, 2025

Incyte announces results from Phase 3 TRuE-PN trial - TipRanks

Mar 09, 2025
pulisher
Mar 09, 2025

Opzelura May Reduce Need for Other Treatments in Atopic Dermatitis | AAD 2025 - Managed Healthcare Executive

Mar 09, 2025
pulisher
Mar 09, 2025

Incyte Co. (NASDAQ:INCY) Stock Position Lowered by Mutual of America Capital Management LLC - Defense World

Mar 09, 2025
pulisher
Mar 08, 2025

For Opzelura, Positive Results from One Trial, Less So From Another | AAD 2025 - Managed Healthcare Executive

Mar 08, 2025
pulisher
Mar 08, 2025

Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study - Quantisnow

Mar 08, 2025
pulisher
Mar 08, 2025

Incyte Corp (INCY) Announces Promising Phase 3 Trial Results for Ruxolitinib Cream in Treating Prurigo Nodularis - GuruFocus.com

Mar 08, 2025
pulisher
Mar 08, 2025

Incyte Corp Says Phase 3 True-Pn1 Study Meets All Primary And Key Secondary Endpoints - Marketscreener.com

Mar 08, 2025
$77.77
price up icon 1.59%
$33.02
price up icon 0.76%
$322.94
price up icon 5.11%
$20.13
price down icon 3.17%
$100.86
price up icon 1.40%
biotechnology ONC
$265.07
price up icon 2.27%
Capitalizzazione:     |  Volume (24 ore):